Companies › Lingyi Biotech
1 active drug program in 1 registered trial: 1 Phase 1; Hematology; next expected readout Jul 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| LY-M001 Injection rAAV8 vector gene therapy expressing glucocerebrosidase (GCase) | GBA | Phase 1 | Gaucher Disease Type 1 | Jul 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06818838 | LY-M001 Injection | Phase 1 | Gaucher Disease Type 1 | Hematology | Jul 2027 |
Spur Therapeutics Prevail Therapeutics Azafaros Bial R&D Investments
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.